Garassino and coworkers recently reported the results of a phase II (ATLANTIC study) involving the administration of durvalumab (anti-PD-L1) as third-line o later treatment for advanced NSCLC subdivided into three subgroups: (a) EGFR/ALK-mutants; (b) non-EGFR/ALK mutants with <25% or at least 25% PD-L1 expression; (c) non-EGFR/ALK-mutants with at least 90% of tumor cells with PD-L1 expression [287]. Here, ALK is linked to neoplasm.